Plasma StabilityADME Services

Plasma Stability

Poor plasma stability can lead to rapid clearance, short half-lives, and poor in vivo performance.  Pharmacokinetic (PK) studies are especially challenging for these compounds as they continue to degrade even after blood is sampled from the study animal, leading to ambiguous PK data.

In the case of prodrugs and antedrugs, rapid degradation in plasma is desirable. If your compounds contain these plasma-labile functional groups, plasma stability should be studied.

We understand that your timelines and budgets are tight, so we’ve coupled high- resolution accurate mass Q-TOF MS with HPLC to help you do more with less. Full-scan data is acquired, from which narrow window extracted ion chromatograms are generated, producing quantitative data equivalent to that obtained by HPLC/MS/MS without the time-consuming process of developing distinct,  MS methods for each test article. The streamlined work flow means data is returned to you on your schedule, enabling you to:

  • Identify plasma-labile structural motifs
  • Prioritize compounds for in vivo animal studies
  • Identify degradation products

assay requirements

Compound Requirements

  • 10 μL of 10 mM stock solution

Test Compound Concentration

  • 1 μM

Time Points

  • Screening: 0 and 15, or 30, or 60 min.
  • in vitro t1/2: 0, 15, 30, 60, and 120 min.


  • Rat
  • Mouse
  • Dog
  • Human

Final Cosolvent Concentration

  • 2.5% DMSO

Analysis Method

  • HPLC-MS – full scan accurate mass data is acquired

Data Delivery

  • Screening: Percent Remaining
  • In vitro t1/2: Half Life, Intrinsic Clearance


Quotes available upon request for:

  • Screening
  • In vitro t1/2

our experts are available to answer your questions